DOR BioPharma, Inc. Release: orBec(R) Pivotal Phase 3 Clinical Trial Results Published In Journal "Blood"

MIAMI, FL -- (MARKET WIRE) -- January 23, 2007 -- DOR BioPharma, Inc. (OTCBB: DORB) (DOR or the Company) announced that data from its pivotal Phase 3 and supportive Phase 2 clinical trials using orBec® (oral beclomethasone dipropionate, or BDP) to treat gastrointestinal Graft-versus-Host disease (GI GVHD) have been pre-published this afternoon in the online edition of Blood, the peer-reviewed Journal of the American Society of Hematology, as a First Edition paper, including long-term survival analyses from these two randomized, double-blinded, placebo-controlled trials not previously made public. Lead author of the study, entitled "A Randomized, Placebo-controlled Trial of Oral Beclomethasone Dipropionate as a Prednisone-Sparing Therapy for Gastrointestinal Graft-versus-Host Disease," is David M. Hockenbery, M.D., Member of the Clinical Research Division, Fred Hutchinson Cancer Research Center and Professor of Medicine, University of Washington School of Medicine, both located in Seattle, Washington. The full article is available online at www.bloodjournal.org.